Horgen

This trial focuses on adults aged 18 and older admitted to Acute Admission Units AAU with non-urgent health complaints such as coughing, back pain, or abdominal discomfort. It aims to evaluate whether using the medidux132 smartphone app after discharge can reduce the rates of readmissions, emergency hospitalizations, and consultations with other medical providers within 7 days. The study compares this app-based monitoring approach with standard post-discharge care to understand its impact on patient outcomes. Participants are randomly assigned to either the intervention arm, where they use the medidux132 app to record symptoms and vital signs daily for 7 days after discharge, or the control arm, which receives usual care without the app. The app provides prompts and guidance to help users manage their symptoms and decide if further medical attention is needed. Follow-up assessments occur at 7 and 28 days post-discharge for all participants to evaluate symptom changes and healthcare use. During the study, participants will complete symptom tracking and vital sign monitoring through the app if in the intervention group, and both groups will attend follow-up consultations at day 7 and day 28. Researchers will measure outcomes including readmission rates, emergency hospitalizations, consultations with medical providers, symptom severity, and app usability. The primary outcome is the incidence of these events within 7 days after initial admission, with additional monitoring up to 28 days to assess longer-term effects.

The Swiss Paediatric Airway Cohort SPAC is a national, ongoing study focused on children and adolescents in Switzerland who visit doctors for repeated wheezing, coughing, and breathing problems related to exercise or sleep. It aims to improve understanding of different clinical types, outcomes, diagnoses, and treatments for these respiratory issues. The study collects real-world data from routine care without performing tests solely for research purposes. Participants are children aged 0 to 16 years referred to paediatric pulmonary outpatient clinics across 10 Swiss hospitals and clinics. Families complete detailed questionnaires at the start, providing information on symptoms, medical history, treatments, and environmental factors. Lung function, allergy, blood, or other tests are done only if needed for clinical care. Follow-up includes monthly questionnaires for the first year and annual questionnaires thereafter to track symptoms and treatments over time. During the study, caregivers and patients 14 years or older provide information through online or postal questionnaires. Medical records from hospitals contribute data on clinical findings, diagnoses, and treatments. The studys main outcomes measured after one year include wheezing, coughing excluding colds, exercise-induced breathing difficulty, and lung function changes. The study plans long-term follow-up with yearly assessments and continues until 2030, supporting research on healthcare and respiratory problems in children.

Gastroentero-pancreatic neuroendocrine tumours GEP-NETs are rare cancers arising from the neuroendocrine cells in the gastrointestinal tract and pancreas. These tumours share common clinical features but their cell biology and mechanisms are not well understood, limiting targeted treatments. The SwissNET registry is designed to collect detailed information to better understand GEP-NETs and improve management strategies in Switzerland. This study collects data prospectively from patients diagnosed with neuroendocrine tumours confirmed by tissue analysis, regardless of the tumours original location. Data entry is anonymized and gathered from hospitals and general practitioners across Switzerland. A study nurse visits contributing centers to review patient files, and a review board addresses conflicting information. The registry monitors treatment approaches including surgery, medical therapy, and peptide-receptor radionuclide therapy. Participants provide informed consent for their data to be included. Researchers regularly evaluate patient outcomes such as tumour-related mortality and hospitalisation rates every five years. The registry also tracks the incidence of GEP-NETs in Switzerland and the effects of different treatments over time. This ongoing data collection aims to improve understanding and guide future care for patients with neuroendocrine tumours.